Your compounded GLP-1 is gone. Here's where to go next.

The FDA ended compounded semaglutide and tirzepatide in 2025. Roughly 300,000 US patients were affected. Answer a few questions and we'll outline the realistic FDA-approved paths available to you today — insurance, manufacturer direct-to-patient, or branded cash-pay.